The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer.

ABSTRACT:

SUBMITTER: Grinshpun A 

PROVIDER: S-EPMC10033931 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature